Trial Profile
Study of cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression and its correlation with clinical outcome in Ipilimumab-treated melanoma patients
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Mar 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Pharmacodynamics; Therapeutic Use
- 13 Mar 2018 New trial record